Allogene Therapeutics (ALLO) Other Non-Current Liabilities (2018 - 2026)

Allogene Therapeutics has disclosed Other Non-Current Liabilities across 9 years of filings, most recently posting $16.1 million for Q1 2026.

• Other Non-Current Liabilities for Q1 2026 came in at $16.1 million, up 42.97% year-over-year; the trailing twelve-month figure through Mar 2026 was $16.1 million (up 42.97% YoY), and the FY2025 annual result was $15.8 million, up 103.63% from the prior year.
• Other Non-Current Liabilities came in at $16.1 million for Q1 2026 at Allogene Therapeutics, up from $15.8 million in the prior quarter.
• In the past five years, Other Non-Current Liabilities ranged from a high of $16.1 million in Q1 2026 to a low of $5.2 million in Q1 2024.
• The 5-year median for Other Non-Current Liabilities is $7.2 million (2022), against an average of $8.7 million.
• Across the five-year window, Other Non-Current Liabilities surged 156.93% in 2022 and retreated 27.42% in 2023, its largest moves.
• Allogene Therapeutics' Other Non-Current Liabilities stood at $5.8 million in 2022, then fell by 11.42% to $5.2 million in 2023, then soared by 49.86% to $7.8 million in 2024, then surged by 103.63% to $15.8 million in 2025, then increased by 2.0% to $16.1 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $16.1 million (Q1 2026), $15.8 million (Q4 2025), and $15.5 million (Q3 2025), per Business Quant data.